Survival of patients who received the third course of postremission intensification therapy according to whether or not G-CSF was part of the regimen. There was no significant difference between the two groups (P = .99) with a median survival time of 2.4 years for patients who did not receive the growth factor (n = 62) and 3.4 years for patients who did receive it (n = 61).